

Amendments to the Claims

1-40. (cancelled)

41. (new) An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

QAFTFSPTYK (SEQ ID NO:638);
LVVDFSQFSR (SEQ ID NO:620);
NVSIPWTHK (SEQ ID NO:625); and
SAICSVVRR (SEQ ID NO:653).

42. (new) The peptide of claim 41, wherein said peptide is 11 amino acids in length.

43. (new) The peptide of claim 41, wherein said peptide is 10 amino acids in length.

44. (new) The peptide of claim 41, wherein said peptide is 9 amino acids in length, and wherein said oligopeptide is selected from the group consisting of:

NVSIPWTHK (SEQ ID NO:625); and
SAICSVVRR (SEQ ID NO:653).

45. (new) The peptide of claim 41, wherein said peptide is fused to a T helper peptide.

46. (new) The peptide of claim 41, wherein said peptide is fused to spacer or linker amino acids.

47. (new) The peptide of claim 41, wherein said peptide is fused to a carrier.

48. (new) The peptide of claim 41, wherein said peptide is linked to a lipid.

49. (new) A fusion protein comprising the peptide of claim 41.

50. (new) A homopolymer of the peptide of claim 41.
51. (new) A heteropolymer of the peptide of claim 41 and a different peptide.
52. (new) A composition comprising the peptide of claim 41 and a carrier.
53. (new) A pharmaceutical composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.
54. (new) A composition comprising the peptide of claim 41 and a liposome.
55. (new) A composition comprising the peptide of claim 41 and one or more second peptides.
56. (new) The composition of claim 54, wherein said peptides form a fusion protein.
57. (new) The composition of claim 54, further comprising a carrier.
58. (new) A pharmaceutical composition comprising the composition of claim 54 and a pharmaceutically acceptable carrier.
59. (new) The composition of claim 54, wherein said peptides are fused by spacer or linker amino acids.